Related Experiment Video
Updated: Dec 8, 2025
09:32
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
15.2K
New biomarkers for checkpoint inhibitor therapy
1Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
ESMO Open
|September 16, 2020
Summary
Predicting patient response to immune checkpoint inhibitors is crucial. This review explores biomarkers, from serum tests to gene expression, to improve treatment selection and minimize toxicity for solid organ malignancies.
Area of Science:
- Oncology
- Immunology
- Biomarker Research
Background:
- Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, particularly for metastatic melanoma.
- However, many patients do not respond to ICIs, and these therapies can cause severe side effects.
Purpose of the Study:
- To review current and emerging biomarkers for predicting patient response to immune checkpoint inhibitor therapy.
- To highlight the need for improved patient selection to maximize efficacy and minimize toxicity.
Main Methods:
- Review of existing literature on predictive biomarkers for ICI therapy.
- Discussion of conventional serum tests (e.g., lymphocyte indices, lactate dehydrogenase) and novel research markers (e.g., interleukin-6, T receptor clonality).
- Exploration of tumorous factors and gene expression profiling as potential predictive tools.
Main Results:
- A wide range of methodologies are being investigated for predictive biomarker discovery.
- Both established and novel markers show potential in predicting response to ICI therapy across various solid organ malignancies.
Conclusions:
- Accurate predictive biomarkers are essential for optimizing immune checkpoint inhibitor therapy selection.
- Further research into these biomarkers will help personalize treatment and reduce patient exposure to ineffective and toxic therapies.
